|
 |
|
 |
Articles |
|
| |
|
|
| |
Clinical Research: Success and Failure in the Sponsor-Vendor Partnership
Susan Bassion, CDISC Lab Team Leader, CDISC, USA |
| |
Establishing a good relationship between a sponsor and a contract research organisation (vendor) is the responsibility of both the sides in the partnership. Sponsor accessibility and responsiveness is a critical piece of the solution. The vendors, in turn, must meet their obligations in a professional manner.
|
|
|
Full Text | More Articles |
|
|
|
|
Pharma Bookshelf |
|
| |
|
|
| |
The Process of New Drug Discovery and Development
Editor(s) - Charles G. Smith, James T. O'Donnell
The Process of New Drug Discovery and Development, Second Edition presents a practical methodology and up-to-date scientific information for maximizing the ability of a multidisciplinary research team to discover and bring new drugs to the marketplace. This new addition updates the scientific advances in new drug discovery and development for areas such as combinatorial chemistry, screening technologies, metabonomics, biotechnology approaches and preclinical testing. It also greatly expands the focus on the business aspects of bringing new drugs to the market and offers coverage of essential topics for companies involved in drug development, such as the financial aspects of starting up a pharmaceutical enterprise, the regulatory process, liability and litigation, and patent law.
Pharmacogenomics
Editor(s) - Werner Kalow, Urs B. Meyer, Rachel F. Tyndale
Reflecting the shift from genetics to genomics in the pharmaceutical sphere, this Second Edition traces the evolution of the science of pharmacogenetics and gathers research from the forefront of the field-spanning the most influential breakthroughs in molecular diagnostics, metabonomics, proteomics, bioinformatics, disease mapping, pharmacodynamics, and disease gene identification.
|
|
|
More Books |
|
|
|
Research Insights |
|
| |
|
|
| |
|
| |
In addition to individual-level protection (i.e., vaccine efficacy), the population-level implications of pre-pandemic vaccine programs should be considered when deciding on stockpile size and dose. Results suggest that a lower vaccine dose may be justified in order to increase population coverage, thereby reducing the infection attack rate overall.
|
| |
Full Text | More Insights |
|
